Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Oct

Today In Oncology

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Related Videos

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Can Long Distance Running Be a Risk Factor for Early-Onset Colorectal Cancer?

FDA Launches Effort to Expand Scientific Expertise, Consumer Voice to Advisory Committees

Multicancer Early Detection Screening Does Not Reduce Overall Late-Stage Cancer Incidence

Cleveland Clinic London Appoints Oncology Vice Chief

NCCN Models How to Tailor Cancer Care for Different Regions During 2026 World Cancer Congress